RRM2B
Ribonucleoside-diphosphate reductase subunit M2 B
As of the edition of 20 October 2026, RRM2B (ribonucleoside-diphosphate reductase subunit M2 B, UniProt Q7LG56) has 6 drugs tested at it and 10 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q7LG56
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Inside the cell
- Solved structures
- 3
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health; Blood and lymph; Lungs and airways; Immune system; Digestive system; Nervous system
- Registered trials of its drugs
- 84
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 2 |
| Went quiet | 1 |
| Stopped | 2 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Motexafin gadolinium | Stopped | Phase 3 | none listed |
| Triapine | Stopped | Phase 3 | none listed |
| TAR-200 | Active | Phase 3 | none listed |
| Gallium citrate | Marketed | Phase 3 | none listed |
| Tezacitabine anhydrous | Went quiet | Phase 2 | none listed |
| FF-10832 | Active | Phase 2 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 2 |
| Undetermined | 8 |
| Total on the list | 10 |